Effect of nebicapone (BIA 3-202) on the the pharmacokinetics of levodopa and catechol O-methyltransferase (COMT) activity in patients with Parkinson's disease

被引：0
|
作者：
Almeida, Luis
Ferreira, Joaquim
Nunes, Teresa
Machado, Rita
Torrao, Leonel
Costa, Joana
Soares, Eva
Rocha, Jose
Falcao, Amilcar
Wright, Lyndon
Soares-da-Silva, Patricio
机构：
[1] Hosp Santa Maria, Dept Neurol, Lisbon, Portugal
[2] Hlth, Catanhede, Portugal
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2007年 / 63卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：784 / 785
页数：2
相关论文
共 50 条
  • [31] Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson's disease
    Lin, Chin-Hsien
    Fan, Jun-Yu
    Lin, Han-I
    Chang, Chia-Wen
    Wu, Yih-Ru
    PARKINSONISM & RELATED DISORDERS, 2018, 50 : 48 - 53
  • [32] BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation
    Parada, A
    Loureiro, AI
    Vieira-Coelho, MA
    Hainzl, D
    Soares-Da-Silva, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 420 (01) : 27 - 32
  • [33] G/A(1947) polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease
    Xie, T
    Ho, SL
    Li, LSW
    Ma, OCK
    MOVEMENT DISORDERS, 1997, 12 (03) : 426 - 427
  • [34] Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic -: Pharmacodynarnic pattern in patients with Parkinson's disease
    Contin, M
    Martinelli, P
    Mochi, M
    Riva, R
    Albani, F
    Baruzzi, A
    MOVEMENT DISORDERS, 2005, 20 (06) : 734 - 739
  • [35] Catechol O-methyltransferase val158met genotype influences frontoparietal activity during planning in patients with Parkinson's disease
    Williams-Gray, Caroline H.
    Hampshire, Adam
    Robbins, Trevor W.
    Owen, Adrian M.
    Barker, Roger A.
    JOURNAL OF NEUROSCIENCE, 2007, 27 (18): : 4832 - 4838
  • [36] A Phase 1 Study of Opicapone Pharmacokinetics and Its Effects on COMT Activity and Levodopa Pharmacokinetics in Patients with Stable Parkinson's Disease
    Loewen, Gordon
    LeWitt, Peter
    Olanow, C. Warren
    Kieburtz, Karl D.
    Liang, Grace S.
    Jimenez, Roland
    Olson, Kurt
    Roberts, Eiry
    ANNALS OF NEUROLOGY, 2019, 86 : S180 - S180
  • [37] Prediction of the effectiveness of tolcapone, a catechol-o-methyltransferase inhibitor, in patients with Parkinson's disease by COMT genotype.
    Chong, DJ
    Suchowersky, O
    Szumlanski, C
    Weinshilboum, RW
    Campbell, NR
    ANNALS OF NEUROLOGY, 1999, 46 (03) : 477 - 477
  • [38] DFT and QSAR study of Catechol-O-methyltransferase (COMT) as inhibitors for Parkinson's disease treatment
    Sherif, Salma
    Sameh, Ahmed
    Salah, Sohaila Mohammed
    Omar, Amina
    Elhaes, Hanan
    Ibrahim, Asmaa
    Refaat, Ahmed
    Ibrahim, Medhat A.
    OPTICAL AND QUANTUM ELECTRONICS, 2024, 56 (04)
  • [39] Depression and Catechol-O-methyltransferase (COMT) genetic variants are associated with pain in Parkinson’s disease
    Chin-Hsien Lin
    K. Ray Chaudhuri
    Jun-Yu Fan
    Chia-I. Ko
    Alexandra Rizos
    Chia-Wen Chang
    Han-I. Lin
    Yih-Ru Wu
    Scientific Reports, 7
  • [40] DFT and QSAR study of Catechol-O-methyltransferase (COMT) as inhibitors for Parkinson’s disease treatment
    Salma Sherif
    Ahmed Sameh
    Sohaila Mohammed Salah
    Amina Omar
    Hanan Elhaes
    Asmaa Ibrahim
    Ahmed Refaat
    Medhat A. Ibrahim
    Optical and Quantum Electronics, 56
12345